The MarketReader Minute
💊 Mesoblast Drops Despite Ryoncil Sales Growth | Biotech Sector Insights
IBB edged lower as declines in Gilead, Amgen, and Regeneron weighed on the sector, extending recent weakness despite broader strength in health insurers following the Medicare Advantage rate update.